Workflows for GLP-1 Receptor Agonists and Therapeutic Peptides: Identity, Impurity, Bioanalysis, and Stability Testing

Significance of the topic

Peptide therapeutics, and notably GLP‑1 receptor agonists (GLP‑1 RAs), now occupy a central role in metabolic disease treatment. Their growing commercial and clinical importance—driven by molecules such as semaglutide and tirzepatide—creates strong demand for robust analytical strategies across the product lifecycle: raw material identity, purity and impurity profiling, bioanalysis (PK/PD), and stability monitoring. Increasing structural complexity (lipidation, non‑canonical residues, linkers) and regulatory expectations require orthogonal, high‑sensitivity, and high‑throughput workflows to ensure safety, efficacy, and manufacturability.

Objectives and overview

This compendium assembles pragmatic analytical workflows and application notes focused on GLP‑1 RAs and related peptides. The objectives are to: 1) demonstrate nondestructive raw material verification, 2) provide orthogonal chromatographic and mass spectrometric approaches for impurity profiling, 3) detail automated sample‑preparation and LC/MS methods for sensitive plasma quantitation, and 4) present complementary stability and structure–function characterization techniques. The driving theme is integration of orthogonal methods (Raman, HILIC, RPLC, single‑quad and high‑resolution MS, UV‑Vis derivative spectroscopy, SPR) to address critical quality attributes (CQAs) efficiently.

Methodology and workflow summary

• Raw material identity: Spatially offset Raman spectroscopy (SORS) using a handheld Agilent Vaya Raman device validated through-container identification of Fmoc‑protected amino acids (HDPE and amber bottles) in <40 s, preserving material integrity.
• Purity and impurity profiling: Hydrophilic interaction liquid chromatography (HILIC) on low‑adsorption/Ultra Inert flow paths (Altura/Poroshell HILIC‑Z columns, Agilent 1290 Infinity III/II Bio LC) coupled to single‑quadrupole (InfinityLab LC/MSD iQ, Pro iQ Plus) or Q‑TOF MS to obtain molecular‑weight confirmation and detect product‑related and degradation impurities (oxidation, truncation, amino‑acid insertion, racemization/isomerization).
• Complementary DAD + ELSD HILIC: Simultaneous measurement of peptide active ingredient(s) and formulation excipients (glycerol, mannitol, phosphate, salts) to profile drug product constituents without separate assays.
• Bioanalysis (plasma): Automated sample cleanup using Agilent AssayMAP Bravo with RP‑S cartridges combined with LC/TQ (Agilent 6495D) MRM assays. Optimized protein precipitation (ACN:MeOH 1:1), cartridge wash/elution (water/10% ACN with ammonium formate and 5% FA in 80% ACN elution) produced 5× sensitivity improvement vs solvent precipitation and achieved LLOQ 0.2 ng/mL (semaglutide) and 0.05 ng/mL (tirzepatide) from 100 µL plasma.
• Stability and structural characterization: UV‑Vis second‑derivative spectroscopy (Agilent Cary 3500 Multicell) to resolve subtle aromatic residue changes under oxidative stress; LC/Q‑TOF (6545XT AdvanceBio) and Pro iQ Plus single‑quad for low‑level degradant detection; integrated LC/MS + SPR workflow linking chemical modifications to receptor binding (Nicoya digital SPR).

Used Instrumentation

• Agilent Vaya Raman handheld SORS system
• Agilent 1290 Infinity III and Infinity II Bio LC systems
• Agilent Altura Poroshell HILIC‑Z and AdvanceBio/Altura peptide columns
• Agilent InfinityLab LC/MSD iQ single‑quadrupole
• Agilent Pro iQ Plus single‑quadrupole MS
• Agilent 6545XT AdvanceBio LC/Q‑TOF
• Agilent 6495D triple quadrupole LC/TQ with Jet Stream ESI
• Agilent AssayMAP Bravo automated sample‑prep platform with RP‑S cartridges
• Agilent Cary 3500 Multicell UV‑Vis Spectrophotometer
• Nicoya Digital Surface Plasmon Resonance (digital SPR) system

Main results and discussion

• Raw‑material ID: Vaya SORS successfully distinguished Fmoc‑protected amino acids through amber glass and thick HDPE containers by detecting characteristic Fmoc bands (~1,481 cm⁻¹) and other aromatic/carbonyl features, enabling nondestructive verification and reducing contamination risk.
• HILIC impurity profiling: HILIC‑MS separated GLP‑1 peptides (semaglutide, exenatide, tirzepatide) and revealed low‑level product‑related impurities: e.g., tirzepatide impurity (+163 Da) consistent with tyrosine addition; semaglutide impurities including stereoisomeric species and truncated or cyclized forms; Exenatide oxidative products (+16 Da) producing partially resolved sulfoxide diastereomers. Single‑quad MS provided rapid MW confirmation and assisted detection of co‑eluting or low‑abundance impurities.
• Low‑adsorption flow path benefits: Eliminating/deactivating stainless‑steel surfaces and using Ultra Inert column hardware markedly improved peak shape, recovery and detection for metal‑sensitive analytes (phosphate, carboxylates) and enhanced impurity visibility—critical for QC workflows.
• Automated bioanalysis: AssayMAP RP‑S purification increased assay sensitivity ~5× over organic precipitation alone; LC/TQ MRM assays were linear across wide ranges and met inter/intraday accuracy and precision criteria. Semaglutide LLOQ 0.2 ng/mL (100 µL plasma), tirzepatide LLOQ 0.05 ng/mL (100 µL) were demonstrated with acceptable CV and bias.
• Derivative UV‑Vis and LC/MS stability: Second‑derivative UV‑Vis rapidly detected tryptophan oxidation and spectral changes for peptides under H2O2 stress; LC/Q‑TOF deconvolution confirmed mono‑ and multi‑oxidation (+16, +32 Da) of liraglutide. Pro iQ Plus single‑quad identified trace oxidized tirzepatide species and an unknown ~+124 Da impurity, showing suitability for routine QC impurity monitoring.
• Integrated structure–function outcome: LC/MS identified multiple oxidized isomers of liraglutide but SPR measurements showed oxidized liraglutide maintained GLP‑1R binding kinetics comparable to native peptide; conversely, chymotrypsin digestion abolished receptor binding. These observations underscore that some chemical modifications do not alter function while backbone cleavage can eliminate activity—highlighting the need to pair structural and functional assays.

Benefits and practical applications

• Raw‑material control: Noninvasive SORS enables faster, contamination‑free verification of sensitive starting materials supporting high‑throughput manufacturing.
• Orthogonal impurity profiling: HILIC (DAD/ELSD) plus MS offers complementary selectivity to RPLC for resolving hydrophilic, isomeric, and fatty‑acid conjugated variants and simultaneous excipient profiling.
• Cost‑effective QC capabilities: Single‑quadrupole MS platforms (InfinityLab LC/MSD iQ, Pro iQ Plus) combined with biocompatible LC hardware provide sensitive, accessible impurity detection for routine QA/QC environments.
• Antibody‑free bioanalysis: Automated LC/TQ workflows with AssayMAP sample cleanup deliver high sensitivity and specificity without ligand‑binding assays, reducing method development time and avoiding cross‑reactivity issues.
• Stability monitoring: UV‑Vis second‑derivative spectroscopy offers a rapid, non‑destructive screen for aromatic residue modifications that can prioritize samples for detailed LC‑MS follow up.
• Decision‑making in development: Coupling LC/MS structural data with SPR functional readouts allows direct assessment of which chemical changes are critical to biological activity, guiding formulation, storage, and candidate selection decisions.

Future trends and potential uses

• Broader adoption of orthogonal, automated workflows in regulated QC labs: combining biocompatible LC hardware with compact MS detectors for routine impurity monitoring.
• Multidimensional separations: HILIC‑RPLC or heart‑cutting approaches to improve resolution of isomeric/truncated peptides and low‑level impurities.
• Integration of high‑throughput sample prep (AssayMAP) with LC/TQ for large PK/PD studies and toxicokinetics in discovery and clinical phases.
• Combined structure–function pipelines: routine pairing of LC/MS characterization with label‑free binding assays (SPR) to accelerate assessment of candidate stability and activity.
• Data analytics and AI: advanced deconvolution, pattern recognition and ML‑assisted impurity annotation to expedite identification of unknown degradants.
• Lower‑cost mass detection in QC: single‑quad detectors with optimized deconvolution will likely expand in regulated environments for day‑to‑day impurity surveillance.

Conclusion

The workflows described provide a coherent, pragmatic toolkit for comprehensive analytical support of GLP‑1 receptor agonists and related peptides. Key takeaways are the value of noninvasive raw‑material verification, the orthogonal selectivity of HILIC for impurity resolution, the practical sensitivity gains from automated AssayMAP cleanup for LC/TQ quantitation, and the necessity of combining structural MS data with functional SPR assays to understand the real impact of chemical modifications. These integrated approaches can reduce analytical risk, accelerate development, and support regulatory compliance for increasingly complex peptide therapeutics.

Reference

1. Prullière F., Welsby C. Differentiating Biopharmaceutical Raw Materials Using Spatially Offset Raman Spectroscopy. Agilent Technologies application note 5991-2013EN, 2021.
2. Alvarez P., Lecluyse C., Vandendriessche I., Sandra P., Sandra K., Schneider S., Huber U. HILIC Analysis of GLP‑1 Receptor Agonists Using an Agilent 1290 Infinity III Bio LC with DAD and ELSD. Agilent application note 5994-8308EN, 2025.
3. McCalley D. V. Understanding and Manipulating the Separation in Hydrophilic Interaction Liquid Chromatography. J. Chromatogr. A 2017, 1523, 49–71.
4. Guimaraes G. J., Bartlett M. G. Managing Nonspecific Adsorption to Liquid Chromatography Hardware: a Review. Anal. Chim. Acta 2023, 1250, 340994.
5. European Medicines Agency. Draft guideline on the development and manufacture of synthetic peptides; EMA/CHMP/CVMP/QWP/387541/2023.
6. Qiu X., Murphy S., Wong D. L. Sensitive Quantitation of Semaglutide from Plasma: automated AssayMAP sample prep and LC/TQ. Agilent application note, 2025.
7. Qiu X., Murphy S., Wong D. L. Sensitive Quantitation of Tirzepatide in Plasma by automated LC/MS. Agilent application note, 2025.
8. Babu S. C. V. Enhanced Peptide Characterization and Stability Assessment Using UV‑Visible Second‑Derivative Spectroscopy on an Agilent Cary 3500 Multicell UV‑Vis Spectrophotometer. Agilent application note 5994‑8551EN, 2025.
9. Miladi M. Impurity Profiling of Tirzepatide Under Stress Conditions Using Agilent Pro iQ Plus. Agilent application note, 2025.
10. Wang J., et al. Mechanistic Study of Diketopiperazine Formation during Solid‑Phase Peptide Synthesis of Tirzepatide. ACS Omega 2022, 7, 46809–46824.